Stock BNO BIONOMICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bionomics Australian S.E.

Equities

BNO

AU000000BNO5

Biotechnology & Medical Research

Delayed Australian S.E.
Other stock markets
 02:10:06 2023-08-24 am EDT 		5-day change 1st Jan Change
0.01 AUD -.--% Intraday chart for Bionomics -.--% -.--%
Mar. 21 Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder CI
Mar. 15 Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: Giugno 2022 2023 2024 2025
Capitalization 1 76.2 26.95 16.4 -
Enterprise Value (EV) 1 76.2 26.95 16.4 16.4
P/E ratio -4.29 x -140 x -0.42 x -0.27 x
Yield - - - -
Capitalization / Revenue 13.9 x 44.9 x 3.22 x 3.22 x
EV / Revenue 13.9 x 44.9 x 3.22 x 3.22 x
EV / EBITDA -3.66 x -0.87 x -0.46 x -0.33 x
EV / FCF - -1,262,864 x - -
FCF Yield - -0% - -
Price to Book - - - -
Nbr of stocks (in thousands) 7,519 8,160 10,693 -
Reference price 2 10.13 3.303 1.533 1.533
Announcement Date 8/25/22 9/29/23 - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Junio 2019 2020 2021 2022 2023 2024 2025
Net sales 1 11.64 3.359 5.581 5.49 0.5996 5.09 5.09
EBITDA 1 -5.833 -1.737 -5.74 -20.8 -30.87 -35.8 -49.1
EBIT 1 -7.542 -4.18 -7.441 -21.91 -32.02 -37.12 -58
Operating Margin -64.78% -124.43% -133.31% -399.05% -5,340.62% -729.39% -1,139.52%
Earnings before Tax (EBT) 1 -9.906 -6.027 - -21.95 -32.05 -36.67 -57.55
Net income 1 -9.669 -7.118 - -21.76 -31.85 -38.66 -59.54
Net margin -83.05% -211.89% - -396.36% -5,311.01% -759.67% -1,169.8%
EPS 2 - - - -2.360 -0.0236 -3.690 -5.655
Free Cash Flow -15.68 - - - -21.34 - -
FCF margin -134.69% - - - -3,559.36% - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 8/20/19 8/28/20 8/25/21 8/25/22 9/29/23 - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 S1 2023 S2 2024 S1
Net sales 4.608 1.528 6.148 -0.5663 0.08 0.08 -0.66 - - 6.15 - 0.7395 -0.1399 -
EBITDA -3.88 - -3.41 -5.93 - - -11.11 - - -5.57 - - - -
EBIT 1 -5.698 1.291 - - -5.79 -5.79 - -3.01 -3.01 - -7.41 -16.3 -15.73 -
Operating Margin -123.66% 84.47% - - -7,237.5% -7,237.5% - - - - - -2,203.75% 11,245.37% -
Earnings before Tax (EBT) 1 -6.543 0.2891 - - -6.57 -6.57 - -4.4 -4.4 - -8.16 -16.31 -15.74 -
Net income 1 -6.364 -0.7083 - - -6.53 -6.53 - -4.35 -4.35 - -8.1 -16.21 -15.64 -15.37
Net margin -138.1% -46.34% - - -8,162.5% -8,162.5% - - - - - -2,191.75% 11,181.89% -
EPS - - - - - - - - - -0.8260 - -0.0142 -0.009400 -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/28/20 8/28/20 2/26/21 8/25/21 2/23/23 2/23/22 2/23/22 8/25/22 8/25/22 8/25/22 2/23/23 2/23/23 9/29/23 3/15/24
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025
Net Debt 3.11 - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) -0.5338 x - - - - - -
Free Cash Flow -15.7 - - - -21.3 - -
ROE (net income / shareholders' equity) -56.3% - - - - - -
ROA (Net income/ Total Assets) -16.6% - - - - - -
Assets 1 58.17 - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 0.1 - - - - - -
Capex / Sales 0.85% - - - - - -
Announcement Date 8/20/19 8/28/20 8/25/21 8/25/22 9/29/23 - -
1AUD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Bionomics

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.533 AUD
Average target price
15.3 AUD
Spread / Average Target
+897.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BNOX Stock
  4. BNO Stock
  5. Financials Bionomics